Clinical Investigation|Articles in Press

Clinical and HRCT features of amyopathic dermatomyositis associated with interstitial lung disease: A retrospective study of 128 patients with connective tissue disease-related interstitial lung disease

Published:December 12, 2022DOI:



      This study retrospectively analyzed the laboratory data and chest images of patients with amyopathic dermatomyositis associated with interstitial lung disease (ADM-ILD) and patients with other connective tissue disease-related ILDs (CTD-ILDs) to find a characteristic index for the early recognition of ADM-ILD and help clinicians consider the possibility of ADM-ILD as soon as possible.


      In our cohort study, the records of 128 Chinese patients with CTD-ILD, including 33 ADM-ILD patients, 37 rheumatoid arthritis (RA)-ILD patients, 33 primary Sjogren's syndrome (pSS)-ILD patients, 14 systemic sclerosis (SSc)-ILD patients and 11 systemic lupus erythematosus (SLE)-ILD patients. The patients’ clinical features, laboratory parameters, and chest HRCT findings were analyzed.


      ADM-ILD patients generally had significantly higher LDH (333.52±160.21 U/L), AST (66.21±83.66 U/L), and CK-MB (18.23±8.28 U/L) levels than other CTD-ILD patients. A total of 90.91% (30/33) of ADM-ILD patients had elevated LDH. Patients with ADM-ILD were more prone to organizing pneumonia radiologic patterns on chest HRCT scans than patients with other CTD-ILDs ( χ 2 =37.39, p < 0.001) and were found in 18 of 33 ADM-ILD patients. Anti-MDA5 (45.45%) was the most commonly detected autoantibody in ADM-ILD patients, followed by anti-PL-7 (21.21%), anti-Jo-1 (12.12%), and anti-PL-12 (9.09%), and levels of ALT (96.93±119.79 vs. 17.50±6.218 U/L), AST (113.00±106.13 vs. 23.56±6.91 U/L), LDH (415.00±198.51 vs. 261.94±67.75 U/L) and CK-MB (22.57±5.91 vs. 14.61±8.36 U/L) were significantly higher in anti-MDA5-positive patients, but these patients had significantly lower WBC counts (4.82±2.61 vs. 7.14±3.00 × 109/L), lymphocyte counts (0.72±0.20 vs. 1.23±0.53 × 109/L), and ALB levels (31.90±4.76 vs. 35.49±4.71 g/L).


      ADM-ILD patients have higher serum LDH, AST and CK-MB levels, especially serum LDH levels, and are more prone to organizing pneumonia radiologic patterns on chest HRCT scans than other CTD-ILD patients. A high level of serum LDH with ILD may be a useful characteristic index for recognizing ADM-ILD.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dalakas M.C.
        Inflammatory muscle diseases.
        N Engl J Med. 2015; 372: 1734-1747
        • Marie I.
        • Hatron P.Y.
        • Dominique S.
        • et al.
        Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.
        Arthritis Rheum. 2011; 63: 3439-3447
        • Nuno-Nuno L.
        • Joven B.E.
        • Carreira P.E.
        • et al.
        Overlap myositis, a distinct entity beyond primary inflammatory myositis: a retrospective analysis of a large cohort from the REMICAM registry.
        Int J Rheum Dis. 2019; 22: 1393-1401
        • Cobo-Ibanez T.
        • Lopez-Longo F.J.
        • Joven B.
        • et al.
        Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease.
        Clin Rheumatol. 2019; 38: 803-815
        • Sontheimer R.D.
        Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?.
        J Am Acad Dermatol. 2002; 46: 626-636
        • Li S.
        • Sun Y.
        • Shao C.
        • et al.
        Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases.
        Rheumatology. 2021; 60 (Oxford): 1195-1204
        • Morganroth P.A.
        • Kreider M.E.
        • Okawa J.
        • et al.
        Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.
        Arch Dermatol. 2010; 146: 729-738
        • Yamaguchi K.
        • Yamaguchi A.
        • Kashiwagi C.
        • et al.
        Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
        Respir Med. 2018; 140: 1-5
        • Sun Y.
        • Liu Y.
        • Yan B.
        • et al.
        Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.
        Rheumatol Int. 2013; 33: 1295-1302
        • Moghadam-Kia S.
        • Oddis C.V.
        • Sato S.
        • et al.
        Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US Patients with amyopathic and myopathic dermatomyositis.
        Arthritis Care Res. 2016; 68 (Hoboken): 689-694
        • Ye S.
        • Chen X.X.
        • Lu X.Y.
        • et al.
        Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
        Clin Rheumatol. 2007; 26: 1647-1654
        • Mukae H.
        • Ishimoto H.
        • Sakamoto N.
        • et al.
        Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis.
        Chest. 2009; 136: 1341-1347
        • Chen Z.
        • Cao M.
        • Plana M.N.
        • et al.
        Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
        Arthritis Care Res. 2013; 65 (Hoboken): 1316-1324
        • Okabayashi H.
        • Ichiyasu H.
        • Hirooka S.
        • et al.
        Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias.
        BMC Pulm Med. 2017; 17: 134
        • Go D.J.
        • Park J.K.
        • Kang E.H.
        • et al.
        Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.
        Rheumatol Int. 2016; 36: 125-131
        • Kotani T.
        • Makino S.
        • Takeuchi T.
        • et al.
        Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis.
        J Rheumatol. 2008; 35: 254-259
        • Travis W.D.
        • Costabel U.
        • Hansell D.M.
        • et al.
        An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
        Am J Respir Crit Care Med. 2013; 188: 733-748
        • Chen Z.
        • Wang X.
        • Ye S.
        Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease.
        N Engl J Med. 2019; 381: 291-293
        • Kurasawa K.
        • Arai S.
        • Namiki Y.
        • et al.
        Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
        Rheumatology. 2018; 57 (Oxford): 2114-2119
        • Kurtzman D.J.
        • Wright N.A.
        • Lin J.
        • et al.
        Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment.
        JAMA Dermatol. 2016; 152: 944-945
        • Gan Y.Z.
        • Zhang L.H.
        • Ma L.
        • et al.
        Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis.
        Chin Med J. 2020; (Engl): 644-649
        • Ideura G.
        • Hanaoka M.
        • Koizumi T.
        • et al.
        Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases.
        Respir Med. 2007; 101: 1406-1411
        • Romero-Bueno F.
        • Diaz Del Campo P.
        • Trallero-Araguas E.
        • et al.
        Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.
        Semin Arthritis Rheum. 2020; 50: 776-790
        • Lian X.
        • Zou J.
        • Guo Q.
        • et al.
        Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model.
        Chest. 2020; 158: 1535-1545
        • Zou J.
        • Guo Q.
        • Chi J.
        • et al.
        HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients.
        Clin Rheumatol. 2015; 34: 707-714
        • Motegi S.I.
        • Sekiguchi A.
        • Toki S.
        • et al.
        Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
        Eur J Dermatol. 2019; 29: 511-517
        • Azuma K.
        • Yamada H.
        • Ohkubo M.
        • et al.
        Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis.
        Mod Rheumatol. 2011; 21: 178-183
        • Huang W.
        • Ren F.
        • Wang Q.
        • et al.
        Clinical features of thirty-two patients with anti-melanoma differentiation-associated gene 5 antibodies.
        Clin Exp Rheumatol. 2019; 37: 803-807
        • Xu Y.
        • Yang C.S.
        • Li Y.J.
        • et al.
        Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
        Clin Rheumatol. 2016; 35: 113-116
        • Tanizawa K.
        • Handa T.
        • Nakashima R.
        • et al.
        HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
        Respir Med. 2011; 105: 1380-1387
        • Egashira R.
        High-resolution CT findings of myositis-related interstitial lung disease.
        Medicina. 2021; 57 (Kaunas)
        • Shao C.
        • Sun Y.
        • Huang H.
        • et al.
        Myositis specific antibodies are associated with isolated anti-Ro-52 associated interstitial lung disease.
        Rheumatology. 2021; (Oxford)
        • Kersey C.B.
        • Oshinsky C.
        • Wahl E.R.
        • et al.
        Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis: case report and literature review.
        J Gen Intern Med. 2021; 36: 3865-3868
        • Kanaoka M.
        • Yamaguchi Y.
        • Watanabe T.
        • et al.
        Clinically amyopathic dermatomyositis with anti-transcriptional intermediary factor 1-gamma autoantibody positivity.
        Rheumatology. 2020; 59 (Oxford): e68-e69
        • Labirua-Iturburu A.
        • Selva-O'Callaghan A.
        • Vincze M.
        • et al.
        Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature.
        Medicine. 2012; 91 (Baltimore): 206-211
        • Keshtkarjahromi M.
        • Chhetri S.
        • Balagani A.
        • et al.
        Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection.
        BMC Rheumatol. 2021; 5: 59
        • Wang G.
        • Wang Q.
        • Wang Y.
        • et al.
        Presence of Anti-MDA5 antibody and its value for the clinical assessment in patients With COVID-19: a retrospective cohort study.
        Front Immunol. 2021; 12791348
        • Quintana-Ortega C.
        • Remesal A.
        • Ruiz de Valbuena M.
        • et al.
        Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
        Mod Rheumatol Case Rep. 2021; 5: 101-107
        • Toquet S.
        • Granger B.
        • Uzunhan Y.
        • et al.
        The seasonality of Dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger.
        Autoimmun Rev. 2021; 20102788
        • Mehta P.
        • Machado P.M.
        • Gupta L.
        Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry.
        Rheumatol Int. 2021; 41: 1021-1036